Newsfeeds - Spark Newswire

1 minute read

Here’s How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today

Today, 7:00 PM

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 16.43% on an annualized basis producing an average annual return of 26.37%. Currently, CRISPR Therapeutics has a market capitalization of $5.08 billion.

CRSP

2 minute read

Why This Analyst Sees A 51% Return On This Cathie Wood-Favored Biotech Stock

By AJ Fabino

Today, 7:00 PM

Biotech stocks have the potential for huge gains if a product or drug is deemed effective and safe, but investing in the shares of those companies can be volatile.

ARKK

1 minute read

$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,900 Today

By Benzinga Insights

Today, 7:00 PM

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 19.58% on an annualized basis producing an average annual return of 31.2%. Currently, CRISPR Therapeutics has a market capitalization of $5.57 billion.

CRSP

1 minute read

Analysts See Softened Timelines For CRISPR Therapeutics’ Sickle Cell Candidate In US

By Vandana Singh

Today, 7:00 PM

Barclays says that CRISPR Therapeutics AG’s (NASDAQ: CRSP) Q2 FY22 earnings release was largely incremental, highlighting the progress of multiple clinical programs, including the…

BLUE

1 minute read

NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday

By Lisa Levin

Today, 7:00 PM

Raymond James cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to $172.92 in pre-market trading.

ACAD

1 minute read

Barclays Downgrades CRISPR Therapeutics to Equal-Weight, Lowers Price Target to $88

By Benzinga Newsdesk

Today, 7:00 PM

Barclays analyst Gena Wang downgrades CRISPR Therapeutics (NASDAQ:CRSP) from Overweight to Equal-Weight and lowers the price target from $99 to $88.

CRSP

1 minute read

SVB Leerink Maintains Outperform on CRISPR Therapeutics, Lowers Price Target to $107

By Benzinga Newsdesk

Today, 7:00 PM

SVB Leerink analyst Rick Bienkowski maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform and lowers the price target from $112 to $107.

CRSP

1 minute read

Cathie Wood Sheds $5M In CRISPR Therapeutics, Scoops Up These Biotech Stocks Instead

By Bhavik Nair

Today, 7:00 PM

Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund.

ARKK

1 minute read

Analyst Ratings

Where CRISPR Therapeutics Stands With Analysts

By Benzinga Insights

Today, 7:00 PM

CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter:

CRSP

1 minute read

Jim Cramer Says This Company Isn’t Making Money

By Priya Nigam

Today, 7:00 PM

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is hearing nothing but positives of late about Nokia Corp (NYSE: NOK) over the previous four weeks. "I think it’s right to buy," he added.

ARLP